WO2009051560A1 - Matière fluorescente soluble dans l'eau à caractère hydrophile et à caractère hydrophobe équilibrés - Google Patents

Matière fluorescente soluble dans l'eau à caractère hydrophile et à caractère hydrophobe équilibrés Download PDF

Info

Publication number
WO2009051560A1
WO2009051560A1 PCT/SG2007/000351 SG2007000351W WO2009051560A1 WO 2009051560 A1 WO2009051560 A1 WO 2009051560A1 SG 2007000351 W SG2007000351 W SG 2007000351W WO 2009051560 A1 WO2009051560 A1 WO 2009051560A1
Authority
WO
WIPO (PCT)
Prior art keywords
molecule
group
backbone
solution
units
Prior art date
Application number
PCT/SG2007/000351
Other languages
English (en)
Inventor
Zhikuan Chen
Xu Li
Junhong Yao
Beiping He
Original Assignee
Agengy For Science, Technology And Research
National University Of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agengy For Science, Technology And Research, National University Of Singapore filed Critical Agengy For Science, Technology And Research
Priority to PCT/SG2007/000351 priority Critical patent/WO2009051560A1/fr
Priority to JP2010529902A priority patent/JP2011500916A/ja
Priority to TW097138687A priority patent/TW200925244A/zh
Publication of WO2009051560A1 publication Critical patent/WO2009051560A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G61/00—Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule
    • C08G61/02—Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G61/00—Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule
    • C08G61/12—Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating
    • C08J3/16—Powdering or granulating by coagulating dispersions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00—Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/10—Organic polymers or oligomers
    • H10K85/111—Organic polymers or oligomers comprising aromatic, heteroaromatic, or aryl chains, e.g. polyaniline, polyphenylene or polyphenylene vinylene
    • H10K85/115—Polyfluorene; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/14—Macromolecular compounds
    • C09K2211/1408—Carbocyclic compounds
    • C09K2211/1416—Condensed systems
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00—Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/10—Organic polymers or oligomers
    • H10K85/151—Copolymers

Definitions

  • the present invention relates to fluorescent materials, particularly water- soluble fluorescent materials and method of forming them.
  • Fluorescent particles are useful in various applications.
  • fluorophores are useful as probes, labels or tags, e.g., in many biochemical fields, such as drug and gene research, cell/microorganism imaging, disease diagnosis, analyte detection, and the like.
  • the aqueous environment is a common environment, it is desirable that the fluorescent particles are soluble in water.
  • many fluorophores are not soluble in water.
  • their performance may be affected by the environment and may be unstable. It is thus desirable to encapsulate the fluorophores with a water-soluble outer layer, which renders the resulting particles soluble in an aqueous solution and insulates the inner fluorophore from the environment.
  • Some conventional fluorescent particles have hydrophobic fluorescent segments and hydrophilic or amphiphilic segments that encapsulate the hydrophobic segments.
  • a drawback of these particles is that in an aqueous environment these particles tend to either aggregate/precipitate or disintegrate, and are unstable. As a result, performance will decay over time. It is thus desirable to improve the stability of fluorescent particles formed from amphiphilic flurorecent molecules. It is known that the stability of particles formed from amphiphilic molecules can be affected by the balance between their hydrophilicity and hydrophobicity. However, it is difficult to predict when the hydrophilicity and hydrophobicity of a particular type of amphiphlic fluorescent polymers is sufficiently balanced for forming stable particles.
  • Amphiphilic molecules are provided for forming fluorescent particles that can remain stable in water.
  • Each molecule comprises a backbone and side chains grafted to the backbone. At least three backbone units are hydrophobic and fluorescent and at least one side chain unit is hydrophilic. The weight ratio within the molecule of backbone and side chain units that are hydrophilic to those that are hydrophobic is from about 1 :4 to about 4:1.
  • a solution comprising water, an organic solvent and the amphiphilic molecule dissolved in the organic solvent is provided.
  • the concentration of the molecule in the solution is from about 1 to about 1000 CAC, such as from about 10 to about 100 CAC, where CAC is the critical aggregation concentration of the amphiphilic molecule.
  • the organic solvent is removed from the solution, thus allowing the amphiphilic molecule to form particles that have a peripheral size from about 10 nm to about 10 microns.
  • the particles can remain stable in water for more than six months.
  • a method of forming fluorescent particles comprises providing a solution comprising water, an organic solvent and an amphiphilic molecule dissolved in the organic solvent; and removing the organic solvent from the solution, thus allowing the amphiphilic molecule to form the fluorescent particles having a peripheral size from about 10 nm to about 10 microns.
  • the amphiphilic molecule comprises a plurality of backbone units forming a molecular backbone and a plurality of side chains grafted to the molecular backbone, with each one of the side chains formed as at least one side chain unit.
  • At least one of the side chain units within the molecule is hydrophilic and at least three of the backbone units are hydrophobic and fluorescent.
  • the weight ratio within the molecule of backbone units and side chain units that are hydrophilic to those that are hydrophobic is from about 1:4 to about 4:1, such as from about 3:7 to about 7:3.
  • the concentration of the amphiphilic molecule in the solution is from about 1 to about 1000 CAC, such as from about 10 to about 100 CAC, wherein the CAC is the critical aggregation concentration of the amphiphilic molecule in the solution.
  • the solution may be prepared by mixing water with a precursor solution that comprises the organic solvent and the amphiphilic molecule. The organic solvent may be removed from the solution by evaporation.
  • the solution may have a pH of about 2 to about 12, and may be at a temperature from about 0 to about 80 0 C, such as from about 4 to about 70 0 C.
  • a water-soluble fluorescent particle formed according to the above method.
  • the particle may comprise a ligand having a specific affinity to a selected target.
  • the ligand may be selected from avidin, biotin, antibody, antigen, and DNA, and the target may be selected from a target molecule, a cell and an organism.
  • a molecule comprising a plurality of backbone units forming a molecular backbone and a plurality of side chains grafted to the molecular backbone, with each one of the side chains formed as at least one side chain unit.
  • At least one of the side chain units within the molecule is hydrophilic and at least three of the backbone units are hydrophobic and fluorescent.
  • the weight ratio within the molecule of backbone units and side chain units that are hydrophilic to those that are hydrophobic is from about 1:4 to about 4:1, such as from about 3:7 to about 7:3.
  • a water-soluble fluorescent particle comprising the molecule described in the preceding paragraph.
  • the particle may comprise a ligand having a specific affinity to a selected target.
  • the ligand may be selected from avidin, biotin, antibody, antigen, and DNA, and the target may be selected from a target molecule, a cell and an organism.
  • the backbone units may comprise fluorene units and the side chains may comprise polyethyleneglycol.
  • the backbone units may comprise an arylene, heteroarylene, arylene vinylene, heteroarylene vinylene, arylene ethylene, or heteroarylene ethylene unit, or a derivative thereof.
  • the backbone units may comprise a unit substituted with an alkyl, alkoxy, alkenyl, alkynyl, alkylsilyl, arylsilylaryl, heteroaryl, aryloxy, heteroaryloxy, alkylthio, alkylamino, dialkylamino, arylamino, diarylamino, aryl ether, heteroaryl ether, aryl thioether, heteroaryl thioether, halogen, cyano, nitro, carbony, thionyl, sulphonyl, or perfluoroalkyl group, or an amino group comprising a heteroaryl group.
  • the backbone units may comprise a phenylene, thienylene, spirobifluorenylene, indenofluorenylene, pyridylene, bipyridylene, carbazoylene, indenocarbazolylene, benzothiazolylene, or oxadiazolylene unit, or a derivative thereof. At least one of the backbone units may be linked to a vinylene group or an ethylene group. At least two of the backbone units may be linked with each other through a single carbon bond, a methylene group, or an atom selected from O, S, N, Si, and P.
  • the backbone units may comprise a flexible group connecting two hydrophobic and fluorescent backbone units. The flexible group may be hydrophilic or hydrophobic.
  • the side chains may comprise side chain units.
  • the side chain units may comprise polyethyleneglycol, polyethyleneimine, polyamide, polyvinylpyrrolidone, polyacrylic acid, polyvinyl alcohol, polylysine, or derivatives thereof. At least one of the side chains may be bonded to the backbone through a single carbon bond, single phosphor bond, ether group, thioether group, amino group, imino group, silyl group, ester group, thioester group, amide group or an imide group.
  • the amphiphilic molecule may have the formula,
  • amphiphilic molecule may have the formula,
  • amphiphilic molecule may have the formula,
  • n is from 1 to 20, and p+q is from 2 to 200.
  • n 1
  • n 1
  • the amphiphilic molecule may have the formula,
  • the above amphiphilic molecule may be formed by forming precursors for the backbone units, the precursors comprising hydrophobic fluorescent groups; grafting hydrophilic groups to the precursors, forming grafted precursors; and linking the grafted precursors, thus forming the amphiphilic molecule.
  • the linking may comprise linking through a coupling reaction.
  • the linking may comprise linking through Suzuki coupling reaction, Grignard coupling reaction, Stille coupling reaction, Heck coupling reaction, Sologashira coupling reaction, oxidation polymerization reaction, reduction polymerization reaction, or polycondensation reaction.
  • FIGS. 1 to 15 are schematic chemical reaction diagrams showing the synthesis routes for respective specific compounds, exemplary of embodiments of the present invention.
  • FIG.16 is a schematic chemical reaction diagram showing a generalized synthesis route of a polymer, exemplary of embodiments of the present invention.
  • FIG.17 is a schematic chemical reaction diagram showing a generalized synthesis route of a polymer with a flexible segment in the backbone, exemplary of embodiments of the present invention.
  • FIGS. 18 to 20 are bar graphs showing measured particles sizes formed of different compounds
  • FIG. 21 is a line graph of measured cell numbers
  • FIG. 22 is a transmission electron microscopy (TEM) image of fluorescent particles formed from a sample compound exemplary of an embodiment of the present invention.
  • FIG. 23 is a transmission electron microscopy (TEM) image of fluorescent particles formed from another sample compound exemplary of an embodiment of the present invention.
  • TEM transmission electron microscopy
  • a graft amphiphilic fluorescent molecule can be used to form stable micellar particles with sufficiently balanced hydrophilicity and hydrophobicity when the weight ratio of the hydrophilic units to the hydrophobic units within the molecule is from about 1 :4 to about 4:1 , such as from about 3:7 to about 7:3.
  • a graft molecule has a molecular backbone and side chains grafted to the backbone and each of said backbone and side chains is formed of at least one backbone unit or side chain unit, respectively.
  • unit as used herein refers to a building block of a particular molecule, for example, where the molecule is formed by polymerizing monomers, the unit is monomeric unit.
  • the backbone includes at least three hydrophobic fluorescent backbone units, and at least one side chain includes at least one hydrophilic side chain unit.
  • the backbone may include only hydrophobic backbone units.
  • the backbone may also include one or more hydrophilic backbone units.
  • a solution comprising water, an organic solvent and the amphiphilic molecule dissolved in the organic solvent is provided.
  • the concentration of the molecule in the solution is from about 1 to about 1000 CAC, such as from about 10 to about 100 CAC, where CAC is the critical aggregation concentration of the amphiphilic molecule.
  • the organic solvent is removed from the solution, thus allowing the amphiphilic molecule to form micellar particles that have a peripheral size from about 10 nm to about 10 microns.
  • the particles can remain stable in water for more than six months.
  • the particles can remain stable in water or an aqueous environment. Particles are considered stable when their sizes remain substantially the same over an extended period of time, such as over a week or up to six months.
  • the particle sizes are considered substantially the same when the variation in size is permissible for the particular application in which the particles are used. For different applications, the permissible size variation may be different.
  • Stability of the particles in an aqueous solution may be determined using any suitable technique.
  • the solution may be inspected visually over time to see if it stays clear. If the particles precipitate or aggregate, precipitation or unclear solution may be observed. If the solution stays clear, the particle sizes in the solution may be measured or monitored using a suitable optical technique such as a light scattering technique. Exemplary methods of particle size measurement are described in, e.g., Z. Yang et al., Langmuir, 2003, vol.19, p.943; and W. Brown et al., J. Phys. Chem., 1991 , vol. 95, p.1850; the contents of each one of which are incorporated herein by reference.
  • the graft molecule may be a conjugated polymer or conjugated oligomer.
  • the backbone is formed of backbone units, which include at least 3 units that are each hydrophobic and fluorescent.
  • the hydrophobic and fluorescent units may be repeating units.
  • the side chains include hydrophilic side chain units.
  • the weight ratio of the hydrophilic side chain units to the hydrophobic repeating units in the molecule may be from about 1 :4 to about 4:1, if no other hydrophobic or hydrophilic segments are present in the molecule. In some embodiments, the weight ratio may be from about 3:7 to about 7:3.
  • the backbone may include an arylene, heteroarylene, arylene vinylene, heteroarylene vinylene, arylene ethylene, or heteroarylene ethylene unit, or a derivative thereof.
  • the term "or" in the preceding sentence or in other similar context indicates that each of the listed items is itself a possible alternative and that any combination of any two or more of the listed items is also a possible alternative.
  • a backbone unit may also be phenylene, thienylene, spirobifluorenylene, indenofluorenylene, pyridylene, bipyridylene, carbazoylene, indenocarbazolylene, benzothiazolylene, oxadiazolylene, or a derivative thereof.
  • the repeating units in the backbone may include fluorene units.
  • a backbone unit may be linked to a vinylene group or an ethylene group.
  • a backbone unit may also be linked to a single or two C-C triple bonds.
  • the backbone units may be linked with each other through a single carbon bond, a methylene group, or an atom selected from O, S, N, Si, and P.
  • the backbone units may include a unit substituted with an organic group.
  • the organic group may be an alkyl, alkoxy, alkenyl, alkynyl, alkylsilyl, arylsilylaryl, heteroaryl, aryloxy, heteroaryloxy, alkylthio, alkylamino, dialkylamino, arylamino, diarylamino, aryl ether, heteroaryl ether, aryl thioether, heteroaryl thioether, halogen, cyano, nitro, carbony, thionyl, sulphonyl, or perfluoroalkyl group, or an amino group that includes a heteroaryl group.
  • the substituted group may be selected to improve the solubility of the result molecule in a selected solvent.
  • the solvent may be an organic solvent, such as tetrahydrofuran (THF), chloroform, dichloromethane, toluene, or the like.
  • THF tetrahydrofuran
  • chloroform chloroform
  • dichloromethane dichloromethane
  • toluene or the like.
  • the molecule may include hexyl substituted fluorene blocks.
  • the backbone may further include a flexible group connecting the fluorescent units in the backbone.
  • the flexible group may be hydrophilic or hydrophobic.
  • the flexible group may be an alkyl group, substituted or unsubstituted alkylene, alkenylene, alkynylene, ether group, thioether group, amino group, imino group, ester group, thioester group, amide group, imide group, silyl group, or the like.
  • the substituents can include any one of the above listed group, any substituted or unsubstituted aryl or heteroaryl group, any hetero atoms, or any combination thereof.
  • the side chains may include side chain units, which in turn include hydrophilic units.
  • Hydrophilic units either in the side chains or in the backbone, may include a polyethyleneglycol (PEG), polyethyleneimine, polyamide, polyvinylpyrrolidone, polyacrylic acid, polyvinyl alcohol, or polylysine unit, or a derivative thereof.
  • the hydrophilic units in the side chains may be bonded to the backbone through a single carbon or phosphor bond, ether group, thioether group, amino group, imino group, silyl group, ester group, thioester group, amide group or an imide group.
  • the hydrophilic side chains may be linked to any position of the backbone, either at the end or in the middle of the backbone.
  • the hydrophilic and hydrophobic units (segments) in the molecule may be readily identified by persons skilled in the art.
  • the weight ratio of these two types of units (segments) within the molecule may then be calculated based on the atomic weights of the elements present in the respective units (segments).
  • the total weight of all hydrophilic segments and the total weight of all hydrophobic segments in the molecule may be respectively calculated and used to calculate their ratio.
  • the weight ratio of the two types of segments in each monomer unit of the polymer may be calculated and used to determine the weight ratio of the entire polymer.
  • the weight ratio may also be determined in another suitable manner known to skilled person in the art.
  • the graft molecule may be formed as follows.
  • the precursors for the backbone units are prepared or obtained from available commercial sources, such as Sigma-AldrichTM, FlukaTM, MerckTM, TCLTM, Alfa AesarTM.
  • the precursors may be prepared using any suitable techniques known to skilled person in the art. At least some of the precursors include hydrophobic fluorescent groups. Side chains including hydrophilic side chain groups are grafted to respective precursors, forming grafted precursors.
  • the grafted precursors may be same or different molecules.
  • the grafted precursors are then linked to form the final graft molecule.
  • the ratio of the side chains to the precursors are selected so that the weight ratio of the hydrophilic segments to the hydrophobic segments is from about 1 :4 to about 4:1 , such as from about 3:7 to about 7:3.
  • Each grafted precursor may be a monomer, an oligomer, or a polymer.
  • the stoichiometric ratio of different grafted precursors in the graft molecule may vary and may be selected depending on the desired backbone size, molecular weight, solubility, bio- compatibility, optical property, or other relevant characteristics.
  • the grafted precursors may be linked together through a coupling reaction.
  • the coupling reaction may be a Suzuki coupling reaction, a Grignard coupling reaction, or a Stille coupling reaction.
  • the grafted precursors may also be linked to form the grafted molecules through oxidation polymerization reaction, reduction polymerization reaction, polycondensation reaction, Heck reaction, Sologashira reaction, or the like.
  • the grafted precursors may be directly linked, or indirectly linked by other backbone units, as can be understood by those skilled in the art.
  • a linking backbone unit that links grafted precursors may have no side chain attached to it or have one or more side chains attached to it.
  • the linking backbone unit may be flexible group.
  • the graft molecules may be formed using other procedures.
  • a polymer backbone may be first prepared and the side chains are then grafted to the backbone in postpolymerization reactions.
  • PEG with OH end groups or amino groups may be grafted to polymer backbones that include alkylbromo groups, acid chloride groups, or anhydride groups.
  • side chains with acid chloride groups or anhydride groups may be grafted to backbones that include OH groups or amino groups.
  • Exemplary postpolymerization techniques are disclosed in Cuihua Xue et a/., "Facile, versatile prepolymerization and postpolymerization functionalization approaches for well-defined fluorescent conjugated fluorene-based glycopolymers", Macromolecules, 2006, vol. 39, no. 17, pp. 5747-5752; K. Buga et ai, "Postpolymerization grafting of aniline tetramer on polythiophene chain: Structural organization of the product and its electrochemical and spectroelectrochemical properties", Chemistry Of Materials, 2005, vol. 17, no. 23, pp. 5754-5762; K.
  • Some exemplary embodiments of the present invention relate to water- soluble fluorescent particles formed from the graft molecules described above.
  • the particles may have a peripheral size from 10 nm to 10 microns.
  • the peripheral size is the particle diameter when the particle is spherical.
  • the peripheral size refers to the effective or average diameter for the particles.
  • An effective diameter of a non-spherical particle is the diameter of a spherical particle that has the same volume as the non- spherical diameter.
  • the size of the particles may be measured using any suitable technique including optical or electronic imaging techniques. For example, the sizes of the particles may be measured using a light scattering technique.
  • the particles may include a ligand having a specific affinity to a selected target.
  • the ligand may be avidin, biotin, antibody, antigen, or DNA
  • the target may be a molecule, a cell or an organism.
  • the particles may be formed as follows.
  • a first solution containing the graft molecules dissolved in an organic solvent is obtained.
  • the organic solvent may be THF, chloroform, dichloromethane, toluene, or the like.
  • the first solution may be a product solution from the formation process for the graft molecule.
  • the product solution may be subject to further optional or necessary treatment depending on the particular case.
  • the first solution may also be separately prepared by dissolving the graft molecules in the organic solvent.
  • the first solution is mixed with water, thus forming a second solution.
  • water or an aqueous solution may be added to the first solution, or the first solution may be added to water or the aqueous solution.
  • the aqueous solution includes water, and may also include a PH buffer solution.
  • the concentration of the graft molecules in the second solution should be controlled. Assuming the particular graft molecule has a critical aggregation concentration, CAC, in the second solution, the concentration of the graft molecules in the second solution should be from about 1 to about 1000 CAC in one embodiment, and from about 10 to about 100 CAC in another embodiment.
  • the CAC for a given graft molecule in a given solution may be determined by monitoring intensity of light emitted from the solution while increasing the concentration of the graft molecule. When the concentration of the graft molecule in the solution is at or near the CAC value, the emission light intensity exhibits a sharp increase.
  • CAC may be measured according to exemplary methods disclosed in, e.g., K. Holmberg et al M Handbook of applied surface and colloid chemistry, 2002, vol. 2, Chapter 13, the contents of which are incorporated herein by reference.
  • the organic solvent is next removed from the second solution, thus allowing the graft molecules to form the particles, such as through self-assembly.
  • the organic solvent may be removed by evaporation, or another technique. For example, a rotary evaporation technique may be used.
  • the evaporation of the organic solvent may be facilitated by exposing the second solution to vacuum, by heating, or by both. In some embodiments, at least 90% of the organic solvent should be removed.
  • the self-assembly process is driven by the hydrophilic and hydrophobic interactions among the different segments in the graft molecules and the water. Generally, hydrophobic segments and water molecules repel each other, while hydrophilic segments and water molecules attract each other.
  • the second solution may have a pH of about 2 to about 12, depending on the application.
  • the second solution may be maintained at a temperature from about 0 0 C to about 80 0 C, such as from about 4 0 C to about 70 0 C.
  • the resulting solution and the formed particles therein may be subject to any suitable post-formation treatment such as extraction, purification, drying, or the like, depending on the application.
  • the particles may be formed using different procedures.
  • the particles may be formed by dissolving amphiphilic block copolymers into a mixture of water and an organic solvent to form a mixture solution, and the organic solvent may be extracted from the mixture solution in different processes.
  • the mixture solution may be transferred into a dialysis tube, which is then immersed into a water bath. Due to concentration differential, the organic solvent will diffuse from the tube into the water bath. The water bath may be refreshed from time to time, such as every two (2) hours. The refreshing process may be repeated until the organic solvent is substantially removed from the solution in the tube. Typically, this process may take two to three days to complete. The remaining solution in the tube will contain the particles formed.
  • the dialysis procedure may be used even when the organic solvent is not very volatile.
  • a further alternative solvent removal technique is the sonication-injection process, which may be used when the organic solvent is volatile, such as THF or acetone.
  • the mixture solution may be slowly injected into a volume of (pure) water under sonication.
  • the resulting solution may be sonicated for a period of time, such as about 10 minutes.
  • the sonicated solution may be stirred at room temperature for e.g. two days to remove the organic solvent by evaporation.
  • the resulting fluorescent particles prepared in the exemplary processes described above are soluble in water and can exhibit stable fluorescent emission over a relatively long period of time such as up to 6 months in an aqueous environment such as in water (see e.g. Example 13 below).
  • nanosized particles are formed using amphiphilic molecules that have similar constituents but the weight ratio of the hydrophilic segments to the hydrophobic segments in the particles are outside the range of 1 :4 to 4:1 , the particles may be unstable in water and their performance as a fluorescent probe is expected to deteriorate over a relatively short period of time, such as within a day to one week.
  • amphiphilic graft polymers 2,7-dibromo-9,9(6'- polyethyleneglycol-hexyl)fluorene and 2-bromo-9,9(6'-polyethyleneglycol- hexyl)fluorene have been found to be unstable in water.
  • the weight ratio of the hydrophilic segments and hydrophobic segments in these two compounds is about 10:1.
  • test results showed that when the weight ratio was in the range from about 1 :4 to about 4:1 , and the concentration of the graft molecules in the second solution was from about 1 to about 1000 CAC, such as from about 10 to about 100 CAC, the tested sample graft molecules formed fluorescent particles that were observed to be stable in water over an extended period of time, such as more than six months.
  • the backbones of the graft molecules include oligofluorene or polyfluorene and the side chains include PEG.
  • THE PEG units may have any suitable size or weight.
  • the grafted precursors for the graft molecules may be linked through a Suzuki coupling reaction.
  • the weight ratio of PEG to oligo- or polyfluorene in the molecules is from about 1 :4 to 4:1 , or from about 3:7 to about 7:3.
  • the organic solvent may be toluene or dichloromethane.
  • the first solution may be added to water drop-wise as the mixed solution is stirred.
  • the organic solvent may be removed by evaporation.
  • the resulting particles may have peripheral sizes from a few nanometers to several micrometers. Both the first solution and the resulting particles when dispersed in water will exhibit intense fluorescence emission.
  • the fluorescence can be measured using a fluorescence spectrometer or a confocal spectrometer.
  • the intense fluorescence exhibited by these particles may be utilized in imaging or detection applications, such as in bio-applications.
  • the particles may be attached to a specific ligand.
  • the ligand may be a nucleotide, single-stranded DNA, double-stranded DNA, single-stranded RNA, double-stranded RNA, a peptide, a protein, a hormone, an antibody, a receptor, an antigen, an epitope, a nucleic acid binding protein, a molecule, an enzyme substrate or an analogue thereof, avidin, streptavidin, biotin, a monosaccharide, a polysaccharide, or the like.
  • the particles with the specific ligand may be used to target a specific cell or an organism.
  • the particle size is generally in the nanometer range, it can be easily up-taken by cells or organisms.
  • the particles can also be prepared so that they are compatible with the selected environment such as the surrounding cells.
  • the components of the particles may be selected so that the presence of the particles would not bring about undesired effects, such as being toxic to the cells.
  • Compound 1 was 2,7-dibromo -(9,9-dihexyl) fluorene, prepared according to the reaction shown in FIG. 1.
  • 2,7-dibromofluorene (9.72g, 30mmol, obtained from Sigma-Aldrich was added to a mixture of aqueous sodium hydroxide (54.3ml, 50%), tetrabutylammonium bromide (1.82g, 5.63mmol), and 1- bromohexane (25.36ml, 180mmol) at 80 0 C. After having been stirred for 5 hours, the mixture was cooled down to room temperature. The mixture was mixed with dichloromethane to extract the reaction product.
  • the organic layers were sequentially washed with water, aqueous HCI, water, and brine.
  • the washed layers were dried using anhydrous MgSO 4 .
  • Remaining solvent and excess 1- bromohexane were removed.
  • the residue was purified using silica gel column chromatography and hexane as the eluent.
  • the purified product contained a white solid, which weighed 14.55g corresponding to a yield of 98.6% by weight.
  • the measured spectra of the white solid were: 1 H NMR (CDCI 3 , 400MHz) ⁇ [ppm]: 7.513 (m, 6H), 1.908 (m, 4H), 1.119 (m, 12H), 0.782 (t, 6H), 0.583 (m, 4H), confirming that the product contained Compound 1 , 2,7-dibromo -(9,9-dihexyl) fluorene.
  • Compound 2 was 2,7-Bis(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)9,9- dihexylfluorene, prepared according to the reaction shown in FIG. 2, using Compound 1.
  • the reaction product in mixture was extracted using ether.
  • the extraction process was repeated 3 times.
  • the extracted organic layers were combined and washed with brine and dried over anhydrous magnesium sulfate.
  • the remaining solvent was removed by rotary evaporation.
  • the purified product contained 1.823g of a white solid (giving a yield of 62% by weight).
  • Compound 3 was 2-bromo-(9,9-dihexyl)fluorene, synthesized according the reaction shown in FIG. 3.
  • 2-bromofluorene (12.25g, ⁇ Ommol) was added to a mixture of aqueous sodium hydroxide (91ml, 50%), tetrabutylammonium bromide (3.03g, 9.38mmol), and 1-bromohexane (42.3ml, 300mmol) at 80 0 C. After having been stirred for 4 hours, the mixture was cooled down to room temperature.
  • This product was Compound 3, 2-bromo-(9,9-dihexyl)fluorene.
  • Example 4 (Synthesis of Compound 4) 10051]
  • Compound 4 was 2-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-9,9- dihexylfluorene, prepared according to the reaction shown in FIG. 4, using compound 3.
  • 6.2g (15mmol) of Compound 3 was mixed with 100 ml anhydrous THF to form a solution.
  • 22.5ml of n-BuLi (27mmol) was added to the solution, which was at -78 0 C.
  • the solution was stirred for one hour before adding 2- isopropoxy-4,4,5,5-tetramethyl-1,3,2 ⁇ dioxaborolane (3.9ml, 18.75mmol) thereto.
  • the measured spectra of the product were 1 H NMR (CDCI3, 400MHz) ⁇ [ppm]: 7.812 (m, 1 H), 7.747 (m, 3H), 7.322 (m, 3H), 7.322 (m, 3H), 1.990 (m, 4H), 1.39 (s, 12H), 1.023 (m, 12H), 0.752 (m, 6H), 0.597 (m, 4H), confirming that the product was Compound 4, 2-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-9,9-dihexylfluorene.
  • Compound 5 was 2,7-dibromo-9,9-bis(6'-bromohexyl)fluorene, prepared according to the reaction shown in FIG. 5. 2,7-dibromofluorene (0.972g, 3mmol) was added to a mixture of aqueous potassium hydroxide (60ml, 50%), tetrabutylammonium bromide (0.198g, O. ⁇ mmol), and 1 ,6-dibromohexane (7.32g, 30mmol) at 75°C. After having been stirred for 15 minutes, the mixture was cooled down to room temperature.
  • the resulting product contained 1.47g (75wt% yield) of a white solid, with measured spectra of 1 H NMR (CDCI 3 , 400MHz) ⁇ (ppm): 7.433-7.535 (m, 6H), 3.294 (t, 4H), 1.923 (m, 4H), 1.652-1.687 (m, 4H), 1.203 (m, 4H), 1.083 (m, 4H), 0.587 (m, 4H), confirming that the product was Compound 5, 2,7-dibromo-9,9-bis(6'-bromohexyl)f!uorene.
  • Example 6 (synthesis of Compound 6) [0055] Compound 6 was 2,7-dibromo-9,9(6'-polyethyleneglycol-hexyl)fluorine, prepared according the reaction shown in FIG. 6, using compound 5. Sodium hydride (0.96g, 40mmol) and anhydrous THF (30ml) were placed in a three-necked 150ml flask under argon atmosphere. PEG (8g, 4mmol) in THF (50ml) was then added drop-wise at room temperature. As shown in FIG.
  • the molecular weight of the PEG used was 2000 Dalton, denoted as PEG2000 or PEG 2 ooo- However, it should be understood that PEG2000 was used for testing purposes and in different embodiments of the present invention the weight of the PEG may vary.
  • Compound 7 was 2-bromo-9,9-bis(6'-bromohexyl)fluorene, prepared according to the reaction shown in FlG. 7.
  • 2-bromofluorene (4.9g, 20mmo!) was added to a mixture of aqueous potassium hydroxide (400ml, 50%), tetrabutylammonium bromide (1.32g, 4mmol), and 1 ,6-dibromohexane (48.8g, 200mmol) at 75°C. After having been stirred for 15 minutes, the mixture was cooled down to room temperature.
  • the product was a light-yellow liquid, weighing 8.6g (75wt% yield), with measured spectra Of 1 H NMR (CDCI 3 , 400MHz) ⁇ (ppm): 7.669 (m, 1H), 7.548 (m, 1H), 7.453 (m, 2H), 7.322 (m, 3H), 3.280 (t, 4H), 1.943 (m, 4H), 1.657 (m, 4H), 1.193 (m, 4H),
  • Compound 8 was 2-bromo ⁇ 9,9(6'-polyethyleneglycol-hexyl)fluorene was synthesized according to the reaction shown in FIG. 8, using compound 7.
  • Example 10 (Synthesis of Compound 10) [0066] Compound 10 was denoted 3F1-PEG2000, prepared according to the reaction shown in FIG. 10, using Compounds 2, 3 and 4. A mixture of Compound 2 (0.15g, 0.25mmol), Compound 4 (1.103g, 0.25mmol), tetrakis(triphenylphosphine)palladium (50mg, 0.04mmol), aqueous sodium carbonate (2M, 1.24ml), and toluene (10.16ml) was deoxygenated and then heated to reflux under nitrogen. The mixture was stirred for 4 hours.
  • the PEG segments are hydrophilic and the other segments are hydrophobic.
  • the weight ratio of hydrophilic to hydrophobic units in a Compound 10 molecule is about 4:1.
  • the CAC of Compound 10 in water is 0.05 mg/mL
  • Compound 11 was 3F2-PEG2000, prepared according to the reaction shown in FIG. 11, using Compounds 4 and 6.
  • a mixture of Compound 4 (0.46g, 1mmol), Compound 6 (1.123g, 0.25mmol), tetrakis(triphenylphosphine)palladium ( 50mg, 0.04mmol), aqueous sodium carbonate (2M, 1.24ml), and toluene (10.16ml) was deoxygenated and then heated to reflux under nitrogen. The mixture was stirred for 2 days and then cooled down to room temperature. The organic solvent in the mixture was allowed to evaporate. The residue was dissolved in 20ml of dichloromethane, and mixed with 800ml of ether to form a precipitate.
  • the weight average molecular weight (M w ) and number-average molecular weight (M n ) of Compound 11 were determined based on gel permeation chromatography (GPC) analysis, with PEG being used as the standard for calibration, and were found to be 4123 and 3969 respectively.
  • GPC gel permeation chromatography
  • the CAC of Compound 11 was measured using a dynamic light scattering (DLS) technique at room temperature in aqueous solution, and was found to be 0.1 mg/mL
  • the CAC of Compound 11 in water is 0.10 mg/mL.
  • Compound 12 was 5F3-PEG2000, prepared according to the reaction shown in FIG. 12, using Compounds 2, 3 and 6.
  • a mixture of Compound 2 (0.23g, 0.4mmol), Compound 3 (0.25g (O. ⁇ mmol), Compound 6 (0.45g, O.immol), tetrakis(triphenylphosphine)palladium ( 32mg, 0.028mmol), aqueous sodium carbonate (2M, 0.88ml), and toluene (2.6ml) was deoxygenated and then heated to reflux under nitrogen. The mixture was under reflux for 2 days and then cooled to room temperature. The organic solvent in the mixture was allowed to evaporate and the residue was dissolved in 20ml of dichloromethane.
  • the solution was mixed with 800ml of ether to form a precipitate.
  • the solvents were removed by centrifuge.
  • the precipitation process was repeated 3 times.
  • the crude product was dissolved in dichloromethane and subject to dialysis using an 8k dialysis tube for about one week.
  • the solution was freeze-dried to form a pale powder product, which was Compound 12.
  • the yield was 46% in this example.
  • the weight ratio of hydrophilic to hydrophobic units in Compound 12 is about 2.4:1.
  • the CAC of Compound 12 was measured using the DLS technique at room temperature in an aqueous solution, and was found to be 0.08 mg/mL.
  • Compound 13 (PF1-PEG2000) was prepared according to the reaction shown in FIG. 13, using Compounds 1 , 2, and 6.
  • a mixture of compound 1 (0.089g, 0.18mmol), Compound 2 (0.117g, 0.2mmol), Compound 6 (0.0898g, 0.02mmol), tetrakis(triphenylphosphine)palladium (2mg, 0.002mmol), aqueous sodium carbonate (2M, 0.284ml), and toluene (1.15ml) was deoxygenated and then heated to reflux under nitrogen. The mixture was under reflux for 2 days and then cooled to room temperature.
  • the organic solvent in the mixture was allowed to evaporate and the residue was dissolved in 4ml dichloromethane.
  • the solution was mixed with 100ml of ether to form a precipitate.
  • the solvents were removed by centrifuge.
  • the precipitation process was repeated 3 times.
  • the crude product was dissolved in dichloromethane and subject to dialysis using a 10k dialysis tube for about one week.
  • the solution was then freeze-dried, forming a light yellow powder product, Compound 13.
  • the resulting product had a particle size of about 85 nm.
  • the yield was 14% in this Example.
  • the measure spectra of the product were 1H NMR (CDCI3, 400MHz) ⁇ [ppm]: 7.854(m, 30H), 7.674(m, 90H), 3.643(m, 360H), 2.129(m, 80H), 1.414(m, 240H), 0.795(m, 200H).
  • the weight ratio of hydrophilic to hydrophobic units in Compound 13 is about 1 :1.6.
  • the CAC of Compound 13 was found to be 0.008 mg/mL.
  • BV-2 cells were cultured for 2 days.
  • An aqueous solution containing 0.3 mg/g of nanoparticles formed from Compound 13 (PF1-PEG2000) was prepared as follows. 3 mg of Compound 13 was dissolved in 1.5 mL of THF to form an initial solution. The initial solution was further diluted with THF until the total volume of the resulting solution was 2 mL. 8 mL of deionized water was slowly added to the resulting solution over 3 hours. The solution was contained in a bottle. The bottle was covered with a piece of KimwipesTM tissue paper, to allow THF to evaporate over a 3-day period. After the 3-day period, water was added to the bottle to adjust the concentration of the final solution which had a total volume of 10 mL. The final solution contained about 0.3 mg/g of Compound 13 (equivalent to about 40 CAC).
  • the solution was added to the culture media with a ratio of 1 :10 (v.v).
  • the cells were kept in the culture media for 6 hours.
  • the cells were fixed with 4% paraformaldehyde for 2 hours and then washed with PBS for 3 times. The cells were observed under a confocal microscope.
  • Two batches of Compound 13 were used in the test.
  • the first batch of Compound 13 was freshly prepared.
  • the second batch of Compound 13 was stored in an aqueous solution at room temperature for at least 6 months. In both cases, the fixed cells showed similar intense fluorescence.
  • the solvents were removed by centrifuge. The precipitation process was repeated 3 times.
  • the crude product was dissolved in dichloromethane and subject to dialysis using a 10k dialysis tube for about one week.
  • the solution was freeze-dried, forming a light yellow powder product, Compound 14.
  • the product particles had a size of about 154 nm.
  • the yield was 37wt%.
  • the weight ratio of hydrophilic to hydrophobic units in Compound 14 is about 1 :0.9.
  • the CAC of Compound 14 was found to be 0.00032 mg/mL [0087]
  • An aqueous solution containing particles formed from Compound 14 was prepared using the same procedure as that described above for Compound 13 by replacing Compound 13 with Compound 14.
  • the final aqueous solution contained about 0.3 mg/mL of Compound 14 (equivalent of about 940 CAC).
  • the micellar particles in the final solution remained stable for 6 months while in storage.
  • Compound 15 was PF3-PEG2000, prepared according to the reaction shown in FIG. 15, using Compounds 1, 2, 6, and 9.
  • the resulting product was a pale powder product, Compound 15.
  • the product particles had a size of about 178 nm.
  • the yield was 21 wt%.
  • the weight ratio of hydrophilic to hydrophobic units in Compound 15 is about 5:2.
  • the CAC of Compound 15 was found to be 0.0004 mg/mL.
  • An aqueous solution containing particles formed from Compound 15 was prepared using the same procedure as that described above for Compound 13 by replacing Compound 13 with Compound 15.
  • the final aqueous solution contained about 0.3 mg/mL of Compound 15 (equivalent of about 750 CAC).
  • the micellar particles in the final solution remained stable for 6 months while in storage.
  • BV-2 cells were cultured for 2 days and then activated for 24 hours by adding different concentration of a simulating agent, lipopolysaccharide.
  • An aqueous solution containing fluorescent particles formed from Compound 13 was prepared as described in Example 13. The solution was added to the cell culture media. The volume ratio of the solution to the culture media was 1 :100. The fluorescence from the media was monitored using a confocal imaging technique. It was observed that when the stimulation intensity was increased (after adding the simulation agent), the fluorescent emission from the cells became stronger, indicating that more fluorescent particles had become engulfed by the activated cells.
  • water-soluble fluorescent polymers may be formed generally according to the reaction shown in FIG. 16, and polymers with flexible segments in the backbone may be prepared according to the reaction shown in FIG. 17.
  • the values of x, y, z, p, q, and n which represent integers, may vary.
  • the value of p+q may vary such as from 2 to 200. Molecules with different sum of p+q may be prepared by adjusting the relative molar or weight ratio of the reactants present in the reaction mixture.
  • a fluorescent polymer that can form stable nanosized particles may be formed as follows. Appropriate amounts of Compounds 1 , 2, and 6 are mixed with tetrakis(triphenylphosphine)palladium, aqueous sodium carbonate, and toluene, to form a mixture. The concentrations of the reactants in the mixture may vary. In one embodiment, the concentration of total reactants may be from 0.1 M to 1.0 M. The mixture may be deoxygenated and then heated to reflux under nitrogen. The mixture may be under reflux and stirred for an extended period such as 2 days to 1 week and then cooled to a lower temperature such as the room temperature. The organic solvent in the mixture is allowed to evaporate.
  • the residue may be dissolved in a minimal amount of dichloromethane or another suitable solvent.
  • the new solution is mixed with a suitable amount of ether to form a precipitate.
  • the volume ratio of the new solution to ether may be from 1:100 to 1:500.
  • the solvents may be removed such as by centrifuge.
  • the precipitation process may be repeated, such as 3 times.
  • the crude product obtained may be dissolved in dichloromethane or another suitable low boiling point solvent, and may be subject to dialysis, such as using a 10k dialysis tube, for an extended period such as from about 3 days to one week.
  • the solution may be freeze-dried to form the final product which contains particles formed from the desired graft molecules.
  • the sizes of the particles may be controlled by changing the molecular structure, molecular weight, or solution concentration.
  • the CAC of the resulting compound was measured using the DLS technique at room temperature in an aqueous solution, and was found to be 0.008 mg/mL
  • the weight average molecular weight (M w ) and number-average molecular weight (M n ) of this sample compound were determined based on GPC analysis, with PEG being used as the standard for calibration, and were found to be 19585 and 9886 respectively.
  • the value of M n was also calculated based on NMR measurement, and was found to be 9976.
  • the GPC result indicated that the sample compound molecule contained only one block in which PEG side chains were attached to a fluorenyl group.
  • a, b, c, d, and r in FIG. 17 also represent integers.
  • the molar ratio between Compound 9 and all other constituents may be from 1 :100 to 1:2, such as from 1 :50 to 1 :2.
  • p may be from 1 to 10
  • q may be from 1 to 200
  • n may be from 1 to 100 such as 1 to 20.
  • the values of a, b, c and d may be selected according to the desired end products.
  • the compound in FIG. 17 is the same as the compound shown in FIG. 16.
  • the sum of p+q may vary such as from 2 to 200.
  • the particles formed from the compounds prepared according the reaction routes shown FIGS. 10 or 17 can also have desired particle size distribution.
  • the particle sizes (effective diameters) of Compound 11 , 12 or 13 in aqueous solutions were from about 10 to about 300 nm.
  • the particle sizes were measured based on transmission electron microscopy (TEM) images of the particles.
  • FIGS. 22 and 23 show exemplary TEM images of fluorescent particles formed from Compound 10 and Compound 11 , respectively.
  • the samples for TEM imaging were prepared as follows. A 90 ⁇ l_ of particle aqueous solution was mixed with 10 ⁇ L 1% PTA aqueous solution by vortex.
  • the particles shown in FlG. 22 had effective diameters ranging from 100 to 200 nm, and the particles shown in FIG. 23 had effective diameters ranging from 10 to 20 nm and from 50 to 80 nm.
  • the particles prepared according to embodiments of the present invention can exhibit good stability in an aqueous environment.
  • the particles can remain stable for more than 6 months in water.
  • graft molecules and particles described above may be used as fluorescent probes, labels or tags in many fields such as biochemical fields. They are useful in drug and gene research, cell/microorganism imaging, disease diagnosis, analyte detection, and the like.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Manufacturing & Machinery (AREA)
  • Composite Materials (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Polyethers (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)

Abstract

Une molécule amphiphile comprend un squelette et des chaînes latérales greffées sur le squelette. Au moins trois unités de squelette sont hydrophobes et fluorescentes et au moins une unité de chaîne latérale est hydrophile. Le rapport en poids à l'intérieur de la molécule du squelette et des unités de chaîne latérale qui sont hydrophiles par rapport à celles qui sont hydrophobes est d'environ 1/4 à environ 4/1. Pour former des particules fluorescentes, on utilise une solution comprenant de l'eau, un solvant organique et la molécule amphiphile dissoute dans le solvant organique. La concentration de la molécule dans la solution est d'environ 1 à 1000 CAC, par exemple d'environ 10 CAC à 100 CAC, CAC représentant a concentration d'agrégation critique de la molécule amphiphile. Le solvant organique est retiré de la solution, ce qui permet à la molécule amphiphile de former des particules qui ont une dimension périphérique d'environ 10 nm à environ 10 microns.
PCT/SG2007/000351 2007-10-17 2007-10-17 Matière fluorescente soluble dans l'eau à caractère hydrophile et à caractère hydrophobe équilibrés WO2009051560A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/SG2007/000351 WO2009051560A1 (fr) 2007-10-17 2007-10-17 Matière fluorescente soluble dans l'eau à caractère hydrophile et à caractère hydrophobe équilibrés
JP2010529902A JP2011500916A (ja) 2007-10-17 2007-10-17 親水性と疎水性のバランスがとれた水溶性蛍光物質
TW097138687A TW200925244A (en) 2007-10-17 2008-10-08 Water-soluble fluorescent material with balanced hydrophilicity and hydrophobicity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SG2007/000351 WO2009051560A1 (fr) 2007-10-17 2007-10-17 Matière fluorescente soluble dans l'eau à caractère hydrophile et à caractère hydrophobe équilibrés

Publications (1)

Publication Number Publication Date
WO2009051560A1 true WO2009051560A1 (fr) 2009-04-23

Family

ID=40567644

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SG2007/000351 WO2009051560A1 (fr) 2007-10-17 2007-10-17 Matière fluorescente soluble dans l'eau à caractère hydrophile et à caractère hydrophobe équilibrés

Country Status (3)

Country Link
JP (1) JP2011500916A (fr)
TW (1) TW200925244A (fr)
WO (1) WO2009051560A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103261087A (zh) * 2010-10-18 2013-08-21 华盛顿大学商业化中心 发色聚合物点
WO2014017983A1 (fr) * 2012-07-25 2014-01-30 National University Of Singapore Nanoparticules à base de polymère conjugué fluorescent à émission élevée dans le rouge lointain/infrarouge proche
CN103804659A (zh) * 2014-02-17 2014-05-21 中国科学院化学研究所 一种带有聚乙二醇单甲醚侧链的噻吩并[3,4-b]噻吩共轭聚合物材料、其制备方法及其应用
CN104004004A (zh) * 2014-04-23 2014-08-27 华中师范大学 一种基于芴为骨架的异氰桥链金的发出白光的化合物、制备与应用
WO2014198669A1 (fr) * 2013-06-10 2014-12-18 Luxcel Biosciences Limited Matiere sensible a l'oxygene et son utilisation pour detecter de l'oxygene dans des espaces tridimensionnels
WO2016073052A1 (fr) * 2014-11-03 2016-05-12 Life Technologies Corporation Monomères et polymères de dibenzosilole, procédés de préparation et d'utilisation de ces derniers
US9797840B2 (en) 2011-11-28 2017-10-24 University Of Washington Through Its Center For Commercialization Highly fluorescent polymer nanoparticle
US10067139B2 (en) 2012-02-03 2018-09-04 University Of Washington Through Its Center For Commercialization Polyelectrolyte-coated polymer dots and related methods
US10150841B2 (en) 2011-12-30 2018-12-11 University Of Washington Through Its Center For Commercialization Chromophoric polymer dots with narrow-band emission
US10191060B2 (en) 2009-11-09 2019-01-29 University Of Washington Functionalized chromophoric polymer dots and bioconjugates thereof
US10514381B2 (en) 2013-03-14 2019-12-24 University Of Washington Through Its Center For Commercialization Polymer dot compositions and related methods
US11208527B2 (en) 2016-04-15 2021-12-28 Beckman Coulter, Inc. Photoactive macromolecules and uses thereof
CN114539537A (zh) * 2022-02-21 2022-05-27 中化国际(控股)股份有限公司 一种锂离子电池电极材料的粘结剂及其制备方法
CN114933693A (zh) * 2022-06-17 2022-08-23 嘉应学院 一种共轭聚合物材料及其制备方法和应用
CN115094379A (zh) * 2022-07-04 2022-09-23 昆明理工大学 一种一维聚芴链及其制备方法
US11584825B2 (en) 2018-12-14 2023-02-21 Beckman Coulter, Inc. Polymer dye modification and applications
US11639937B2 (en) 2006-10-06 2023-05-02 Sirigen Ii Limited Fluorescent methods and materials for directed biomarker signal amplification
WO2023177853A1 (fr) * 2022-03-17 2023-09-21 Markushin Yuriy Compositions d'amélioration et utilisations associées
US11874278B2 (en) 2010-01-19 2024-01-16 Sirigen Ii Limited Reagents for directed biomarker signal amplification

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2691962A4 (fr) * 2011-03-28 2015-04-22 Hitachi Chemical Res Ct Inc Polymères conjugués de réseau présentant une meilleure solubilité
US8835000B2 (en) * 2011-12-23 2014-09-16 General Electric Company High-density fluorescent dye clusters
JP2016525595A (ja) * 2013-07-11 2016-08-25 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション フッ化ポリマードット

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055122A1 (fr) * 2001-01-11 2002-07-18 Biocompatibles Uk Limited Protheses endovasculaires presentant un revetement polymere amphiphile qui renferme un medicament
WO2002055121A1 (fr) * 2001-01-11 2002-07-18 Biocompatibles Uk Limited Apport de medicament en provenance de stent
WO2005100437A1 (fr) * 2004-04-14 2005-10-27 Kanazawa University Technology Licensing Organization Ltd. Dérivé de polyfluorène ayant une luminescence particulière et procédés servant à produire celui-ci
WO2007027159A1 (fr) * 2005-08-30 2007-03-08 Agency For Science, Technology And Research Particule fluorescente hydrosoluble comprenant un polymère fluorescent et une molécule amphiphile enchevêtrés

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001481D0 (en) * 2000-01-21 2000-03-15 Theryte Ltd System for delivering a medicament
US7241512B2 (en) * 2002-04-19 2007-07-10 3M Innovative Properties Company Electroluminescent materials and methods of manufacture and use
JPWO2005121203A1 (ja) * 2004-04-14 2008-04-10 有限会社金沢大学ティ・エル・オー 高い蛍光量子収率を示す共役系高分子と金属塩とのハイブリッド体、その製造方法及びそれを用いた蛍光発光材料
GB2433512B (en) * 2004-10-11 2009-06-03 Cambridge Display Tech Ltd Polar semiconductive hole transporting material
WO2006095668A1 (fr) * 2005-03-09 2006-09-14 Toray Industries, Inc. Microparticule et composition pharmaceutique

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055122A1 (fr) * 2001-01-11 2002-07-18 Biocompatibles Uk Limited Protheses endovasculaires presentant un revetement polymere amphiphile qui renferme un medicament
WO2002055121A1 (fr) * 2001-01-11 2002-07-18 Biocompatibles Uk Limited Apport de medicament en provenance de stent
WO2005100437A1 (fr) * 2004-04-14 2005-10-27 Kanazawa University Technology Licensing Organization Ltd. Dérivé de polyfluorène ayant une luminescence particulière et procédés servant à produire celui-ci
WO2007027159A1 (fr) * 2005-08-30 2007-03-08 Agency For Science, Technology And Research Particule fluorescente hydrosoluble comprenant un polymère fluorescent et une molécule amphiphile enchevêtrés

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Derwent World Patents Index; Class A96, AN 2002-291232 *
DATABASE WPI Derwent World Patents Index; Class A96, AN 2002-632207 *
DATABASE WPI Derwent World Patents Index; Class A96, AN 2002-713304 *
DATABASE WPI Derwent World Patents Index; Class A96, AN 2006-240171 *
ZHANG, ZHI-JIAN ET AL.: "Synthesis and characterization of a novel water-soluble block copolymer with a rod-coil structure", MATERIALS LETTERS, vol. 60, no. 5, 2006, pages 679 - 684 *

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11639937B2 (en) 2006-10-06 2023-05-02 Sirigen Ii Limited Fluorescent methods and materials for directed biomarker signal amplification
US10191060B2 (en) 2009-11-09 2019-01-29 University Of Washington Functionalized chromophoric polymer dots and bioconjugates thereof
US11835526B2 (en) 2009-11-09 2023-12-05 University Of Washington Functionalized chromophoric polymer dots and bioconjugates thereof
US11249086B2 (en) 2009-11-09 2022-02-15 University Of Washington Functionalized chromophoric polymer dots and bioconjugates thereof
US11899018B2 (en) 2010-01-19 2024-02-13 Sirigen Ii Limited Reagents for directed biomarker signal amplification
US11874278B2 (en) 2010-01-19 2024-01-16 Sirigen Ii Limited Reagents for directed biomarker signal amplification
US10739349B2 (en) 2010-10-18 2020-08-11 University Of Washington Through Its Center For Commercialization Chromophoric polymer dots
CN109233810A (zh) * 2010-10-18 2019-01-18 华盛顿大学商业化中心 发色聚合物点
JP2014500891A (ja) * 2010-10-18 2014-01-16 ユニバーシティ オブ ワシントン センター フォー コマーシャライゼーション 発色団ポリマードット
JP2017082223A (ja) * 2010-10-18 2017-05-18 ユニバーシティ オブ ワシントン センター フォー コマーシャライゼーション 発色団ポリマードット
CN109233810B (zh) * 2010-10-18 2022-05-03 华盛顿大学商业化中心 发色聚合物点
US9810693B2 (en) 2010-10-18 2017-11-07 University Of Washington Through Its Center For Commercialization Chromophoric polymer dots
CN103261087A (zh) * 2010-10-18 2013-08-21 华盛顿大学商业化中心 发色聚合物点
US11585818B2 (en) 2010-10-18 2023-02-21 University Of Washington Through Its Center For Commercialization Chromophoric polymer dots
JP2020019785A (ja) * 2010-10-18 2020-02-06 ユニバーシティ オブ ワシントン センター フォー コマーシャライゼーション 発色団ポリマードット
US9382473B2 (en) 2010-10-18 2016-07-05 University Of Washington Through Its Center For Commercialization Chromophoric polymer dots
US9797840B2 (en) 2011-11-28 2017-10-24 University Of Washington Through Its Center For Commercialization Highly fluorescent polymer nanoparticle
US11697713B2 (en) 2011-12-30 2023-07-11 University Of Washington Through Its Center For Commercialization Chromophoric polymer dots with narrow-band emission
US10150841B2 (en) 2011-12-30 2018-12-11 University Of Washington Through Its Center For Commercialization Chromophoric polymer dots with narrow-band emission
US10067139B2 (en) 2012-02-03 2018-09-04 University Of Washington Through Its Center For Commercialization Polyelectrolyte-coated polymer dots and related methods
US10768180B2 (en) 2012-02-03 2020-09-08 University Of Washington Through Its Center For Commercialization Polyelectrolyte-coated polymer dots and related methods
WO2014017983A1 (fr) * 2012-07-25 2014-01-30 National University Of Singapore Nanoparticules à base de polymère conjugué fluorescent à émission élevée dans le rouge lointain/infrarouge proche
US10514381B2 (en) 2013-03-14 2019-12-24 University Of Washington Through Its Center For Commercialization Polymer dot compositions and related methods
WO2014198669A1 (fr) * 2013-06-10 2014-12-18 Luxcel Biosciences Limited Matiere sensible a l'oxygene et son utilisation pour detecter de l'oxygene dans des espaces tridimensionnels
CN103804659B (zh) * 2014-02-17 2016-09-21 中国科学院化学研究所 一种带有聚乙二醇单甲醚侧链的噻吩并[3,4-b]噻吩共轭聚合物材料、其制备方法及其应用
CN103804659A (zh) * 2014-02-17 2014-05-21 中国科学院化学研究所 一种带有聚乙二醇单甲醚侧链的噻吩并[3,4-b]噻吩共轭聚合物材料、其制备方法及其应用
CN104004004A (zh) * 2014-04-23 2014-08-27 华中师范大学 一种基于芴为骨架的异氰桥链金的发出白光的化合物、制备与应用
US10570250B2 (en) 2014-11-03 2020-02-25 Life Technologies Corporation Dibenzosilole monomers and polymers and methods for their preparation and use
US10087280B2 (en) 2014-11-03 2018-10-02 Life Technologies Corporation Dibenzosilole monomers and polymers and methods for their preparation and use
WO2016073052A1 (fr) * 2014-11-03 2016-05-12 Life Technologies Corporation Monomères et polymères de dibenzosilole, procédés de préparation et d'utilisation de ces derniers
US11208527B2 (en) 2016-04-15 2021-12-28 Beckman Coulter, Inc. Photoactive macromolecules and uses thereof
US11834551B2 (en) 2016-04-15 2023-12-05 Beckman Coulter, Inc. Photoactive macromolecules and uses thereof
US11584825B2 (en) 2018-12-14 2023-02-21 Beckman Coulter, Inc. Polymer dye modification and applications
US12018117B2 (en) 2018-12-14 2024-06-25 Beckman Coulter, Inc. Polymer dye modification and applications
CN114539537B (zh) * 2022-02-21 2023-06-06 中化国际(控股)股份有限公司 一种锂离子电池电极材料的粘结剂及其制备方法
CN114539537A (zh) * 2022-02-21 2022-05-27 中化国际(控股)股份有限公司 一种锂离子电池电极材料的粘结剂及其制备方法
WO2023177853A1 (fr) * 2022-03-17 2023-09-21 Markushin Yuriy Compositions d'amélioration et utilisations associées
CN114933693A (zh) * 2022-06-17 2022-08-23 嘉应学院 一种共轭聚合物材料及其制备方法和应用
CN114933693B (zh) * 2022-06-17 2023-08-22 嘉应学院 一种共轭聚合物材料及其制备方法和应用
CN115094379B (zh) * 2022-07-04 2024-01-12 昆明理工大学 一种一维聚芴链及其制备方法
CN115094379A (zh) * 2022-07-04 2022-09-23 昆明理工大学 一种一维聚芴链及其制备方法

Also Published As

Publication number Publication date
JP2011500916A (ja) 2011-01-06
TW200925244A (en) 2009-06-16

Similar Documents

Publication Publication Date Title
WO2009051560A1 (fr) Matière fluorescente soluble dans l'eau à caractère hydrophile et à caractère hydrophobe équilibrés
Stals et al. Folding polymers with pendant hydrogen bonding motifs in water: The effect of polymer length and concentration on the shape and size of single-chain polymeric nanoparticles
US8324358B2 (en) Polymer compositions and uses thereof
Liu et al. Syntheses and applications of dendronized polymers
US8394914B2 (en) Functional polyglycolide nanoparticles derived from unimolecular micelles
Zheng et al. A tetraphenylethylene (TPE)-based supra-amphiphilic organoplatinum (ii) metallacycle and its self-assembly behaviour
Yang et al. Hydrophobic-sheath segregated macromolecular fluorophores: colloidal nanoparticles of polycaprolactone-grafted conjugated polymers with bright far-red/near-infrared emission for biological imaging
US8455265B2 (en) Surface grafted conjugated polymers
Kamps et al. Self-assembly of amphiphilic conjugated diblock copolymers into one-dimensional nanoribbons
KR101348074B1 (ko) 형광 고분자 기반 실리카 나노입자의 제조방법
Lavasanifar et al. The effect of alkyl core structure on micellar properties of poly (ethylene oxide)-block-poly (L-aspartamide) derivatives
Murphy et al. Precise synthesis of poly (macromonomer) s containing sugars by repetitive ROMP and their attachments to poly (ethylene glycol): synthesis, TEM analysis and their properties as amphiphilic block fragments
Hu et al. Conjugated Polyelectrolytes with Aggregation‐Enhanced Emission Characteristics: Synthesis and their Biological Applications
Li et al. Autofluorescent Polymers: 1 H, 1 H, 2 H, 2 H-Perfluoro-1-decanol Grafted Poly (styrene-b-acrylic acid) Block Copolymers without Conventional Fluorophore
CN101260219A (zh) 一种用于实现可逆荧光调控的三嵌段共聚物胶束体系的制备方法
JPWO2011162366A1 (ja) 水溶性ポリマー及び水溶性ナノ粒子複合体
Rasheed et al. Block copolymer self-assembly mediated aggregation induced emission for selective recognition of picric acid
Carrillo et al. Biofunctionalized block copolymer nanoparticles based on ring‐opening metathesis polymerization
Huang et al. Water-soluble fluorescent nanoparticles from supramolecular amphiphiles featuring heterocomplementary multiple hydrogen bonding
Zhan et al. Design, synthesis, and adhesion of fluorescent conjugated polymers with pendant catechol groups
Zhou et al. Switchable glucose-responsive volume phase transition behavior of poly (phenylboronic acid) microgels
WO2021198311A1 (fr) Marqueur électroluminescent
Deepak et al. Photophysical Investigation into the self-organization in pyrene-based urethane methacrylate comb polymer
Steverlynck et al. Strategies toward controlling the topology of nonlinear poly (thiophenes)
Chen et al. A novel AIE-active dye for fluorescent nanoparticles by one-pot combination of Hantzsch reaction and RAFT polymerization: synthesis, molecular structure and application in cell imaging

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07835506

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010529902

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07835506

Country of ref document: EP

Kind code of ref document: A1